Interestingly the GLP-1 receptor (GLP1R) agonists liraglutide and semaglutide as well as the orlistat have shown beneficial effects on the two hits typical of NAFLD, the hepatic steatosis and the inflammatory process (for review see (Polyzos et al., 2022)). This evidence concerns the gene GLP1R and fatty liver disease.